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Abstract
Adipose tissue contains self-renewing multipotent cells termed mesenchymal stromal cells. In situ, these cells serve to expand
adipose tissue by adipogenesis, but their multipotency has gained interest for use in tissue regeneration. Little is known regarding
the repertoire of receptors expressed by adipose-derived mesenchymal stromal cells (AD-MSCs). The purpose of this study was
to undertake a comprehensive analysis of purinergic receptor expression. Mesenchymal stromal cells were isolated from human
subcutaneous adipose tissue and confirmed by flow cytometry. The expression profile of purinergic receptors was determined by
quantitative real-time PCR and immunocytochemistry. The molecular basis for adenine and uracil nucleotide-evoked intracel-
lular calcium responses was determined using Fura-2 measurements. All the known subtypes of P2X and P2Y receptors,
excluding P2X2, P2X3 and P2Y12 receptors, were detected at the mRNA and protein level. ATP, ADP and UTP elicited
concentration-dependent calcium responses in mesenchymal cells (N = 7–9 donors), with a potency ranking ADP (EC50
1.3 ± 1.0 μM) >ATP (EC50 2.2 ± 1.1 μM) =UTP (3.2 ± 2.8 μM). Cells were unresponsive to UDP (< 30 μM) and UDP-
glucose (< 30μM). ATP responses were attenuated by selective P2Y2 receptor antagonism (AR-C118925XX; IC50 1.1 ± 0.8μM,
73.0 ± 8.5% max inhibition; N = 7 donors), and UTP responses were abolished. ADP responses were attenuated by the selective
P2Y6 receptor antagonist, MRS2587 (IC50 437 ± 133nM, 81.0 ± 8.4%max inhibition;N = 6 donors). These data demonstrate that
adenine and uracil nucleotides elicit intracellular calcium responses in human AD-MSCs with a predominant role for P2Y2 and
P2Y6 receptor activation. This study furthers understanding about how human adipose-derived mesenchymal stromal cells can
respond to external signalling cues.
Keywords Adipose tissue . AR-C118925XX .MRS2578 . ATP . ADP
Introduction
Adipose tissue is an abundant and easily accessible source of
mesenchymal stromal cells (MSCs) in adult humans. MSCs
are multipotent plastic-adherent cells that can be isolated from
bone marrow and other tissues, including adipose [1]. In adult
adipose tissue, a pool of MSCs serves to replace
approximately 10% of mature adipocytes annually via adipo-
genesis [2]. Both adipogenesis and hypertrophic mechanisms
are important for the expansion of adipose tissue and body
buffering of glucose and free fatty acids. Lower rates of adi-
pogenesis are associated with increased visceral obesity, adi-
pocyte hypertrophy and higher fasting blood glucose levels
[3]. This suggests that efforts to improve the adipogenic po-
tential of MSCs may oppose metabolically unhealthy pheno-
types. The multipotency of adipose-derived (AD)-MSCs [1,
4] has led to clinical trial evaluation of AD-MSCs usage for
regenerative tissue damage [5–7]. Despite some promise in
tissue regeneration studies, MSC senescence and induced in-
flammation are common drawbacks to therapy [8, 9]. A great-
er understanding of how MSCs respond to their environment
via cell surface receptors will therefore delineate MSC
function.
Signalling via extracellular nucleotides has been implicated
in cell migration, proliferation, differentiation and inflamma-
tion [10, 11]. The biological effects of ATP are mediated by
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P2X receptors (P2X1-7), a family of trimeric cation ion chan-
nels [12, 13], and metabotropic responses to ATP, ADP, UTP,
UDP and UDP-sugars are mediated by eight P2Y receptors in
a subtype-specific fashion [14]. P2Y1, P2Y2, P2Y4, P2Y6 and
P2Y11 receptors are Gq-coupled, so upon agonist binding they
activate phospholipase C (PLC) and subsequently induce re-
lease of calcium (Ca2+) from intracellular stores, whereas
P2Y12, P2Y13 and P2Y14 receptors are Gi-coupled and conse-
quently suppress adenylyl cyclase activity [15]. Receptor-
mediated intracellular Ca2+ signals are known to be important
for cellular proliferation and differentiation, and studies have
demonstrated stem cell sensitivity to extracellular ATP [16].
However, current work has primarily focused on rodent
models and bone marrow-derived MSCs (BM-MSC) or has
failed to report the molecular basis of purinergic responses
[17, 18]. For example, extracellular nucleotides elicit
reorganisation of actin filaments and cell migration in 3T3-
L1 mouse adipocyte precursors [19], and ATP promotes
adipogenic and osteogenic differentiation in BM-MSCs [20].
This study focuses on the molecular identity of receptors used
by human AD-MSCs to respond to physiologically relevant
extracellular nucleotides and elevate cytoplasmic calcium.
Methods
Chemicals and antibodies
All chemicals were purchased from Sigma-Aldrich (Dorset,
UK) unless otherwise stated. Selective antagonists were ob-
tained fromTocris Bioscience (Bristol, UK) (P2Y1MRS2500;
P2Y2 AR-C118925XX; P2Y6 MRS2578; P2Y11 NF340;
P2Y12 PSB-0739; P2Y13 MRS2211; P2X4 PSB12062;
P2X7 A438079), excluding thapsigargin (sarco-endoplasmic
reticulum Ca2+-ATPases, SERCA) and U73122 (PLC) (Santa
Cruz Biotechnology, Texas, USA). Nucleotides were pur-
chased from Abcam (Cambridge, UK), except ADP (Sigma-
Aldrich, Dorset, UK). Primary antibodies were purchased
from Santa Cruz Biotechnology (Dallas, TX, USA) (P2X1
sc-31491; P2X5 sc-15192), Alomone Labs (Jerusalem,
Israel) (P2X4, APR-002; P2X7, APR-004; P2Y1, APR-009;
P2Y4, APR-006; P2Y6, APR-011; P2Y11, APR-015; P2Y12,
APR-020; P2Y13, APR-017) and Abcam (Cambridge, UK)
(P2Y2, ab10270). Phycoerythrin (PE)-conjugated IgG1
isotype control (400113), CD14 (367103), CD45 (368509),
CD73 (344003), CD90 (328109) and CD105 (323205) anti-
bodies were all purchased from Biolegend (San Diego, CA,
USA).
Tissue donation
Subcutaneous abdominal adipose tissue samples were obtain-
ed from 48 healthy female volunteers, who have had
mastectomies as part of their past treatment for breast cancer
and subsequently choose to have breast reconstructions via
elective delayed deep inferior epigastric perforator flap oper-
ations. All volunteers were screened to exclude diabetics, cur-
rent cancer sufferers, patients currently receiving chemother-
apy, donors with infections or taking anti-inflammatory med-
ication. The donors had an average age of 55.5 ± 1.4 (range
38–75). Samples were obtained with the assistance of the
plastic surgery team at the Norfolk and Norwich University
Hospital (NNUH). Informed consent was obtained from all
volunteers prior to participation in the study.
This study was ethically approved by the London-Stanmore
Research Ethics Committee (152093) and the Research and
Development department at the NNUH (2014EC03L).
Primary cell isolation from adipose tissue
Fresh adipose tissue samples were dissected to remove blood
vessels, fibrous tissue and skin. The samples were then further
minced and enzymatically digested with collagenase and
DNase I for 30 min at 37 °C with regular mixing by inversion.
The digested tissue samples were then passed through a
70-μm cell strainer and centrifuged for 5 min at 450×g, which
separated the sample into a floating fraction containingmature
adipocytes and a pellet containing MSCs. The adipocytes
were discarded and theMSCs were treated with a red cell lysis
buffer, washed and then resuspended in DMEM supplement-
ed with 4.5 g/L glucose, L-glutamine, 10% FBS (v/v), 50 IU/
ml penicillin and 50 μg/ml streptomycin and left in a T175
flask overnight in a humidified incubator at 37 °C in 5% CO2.
The following day, the cells were washed twice with PBS to
remove any non-adherent cells or debris and left in fresh
serum-containing media until the cells were confluent, at
which point they were trypsinised and plated for experimental
use. MSCs were passaged up to eight times for experimental
use, but the majority of experiments were performed between
passage one and four.
Flow cytometry
MSCs were trypsinised and resuspended in PBS at a density
of 1 × 106 cells/ml and then 100 μl of cells were placed in
individual tubes for each marker and control required. All
steps were conducted at room temperature. The cells were
incubated with 5 μg/ml of human BD Fc block™ (BD
Pharmingen, New Jersey, USA) for 10 min. Next, PE-
conjugated antibodies (1:33) were added to detect cell surface
expression of CD14, CD45, CD73, CD90 and CD105 and the
cells were incubated in the dark for a further 30 min. An
isotype control (1.33) and an unstained control were also run
alongside these markers. The cells were then washed once
with PBS and resuspended in 200 μl of fresh PBS. Samples
were then analysed using a Beckman Coulter CytoFLEX flow
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cytometer (California, USA). Fluorescence intensity was read
for PE (excitation 496 nm, emission 578 nm). Living cells
were gated according to their forward and side scatter and then
histograms were plotted to compare the fluorescence signal
for each marker versus the isotype control using CytExpert
1.2.11 software (Beckman Coulter, California, USA).
Calcium mobilisation experiments
MSCs were seeded at 2 × 104 cells per well in black glass
bottom 96-well plates (Molecular Devices, California, USA)
and incubated at 37 °C in 5%CO2 for 48 h. The growth media
was then aspirated off and the cells were gently washed with
salt buffered solution (SBS) (pH 7.4), containing 130 mM
sodium chloride, 5 mM potassium chloride, 1.2 mM magne-
sium chloride, 1.5 mM calcium chloride, 8 mMD-(+)-glucose
and 10 mM HEPES. The cells were then loaded with 2 μM
Fura-2AM (TEFLabs, Austin, TX, USA) in SBS supplement-
ed with 0.01% (w/v) pluronic for 1 h at 37 °C while being
protected from light. The loading buffer was then removed
and the cells were washed twice with SBS. Where applicable,
the cells were incubated for a further 30 min with antagonists/
vehicle or calcium-free SBS (SBS lacking 1.5 mM calcium
chloride, but containing 2 mMEGTA, pH7.4). All antagonists
were dissolved in water or DMSO and were then further di-
luted in SBS, so that a final concentration of 1% DMSO was
never exceeded. Finally, the cells were maintained at 37 °C
and challenged with nucleotides administered as a single pi-
pette drop by a FlexStation III microplate reader (Molecular
Devices, California, USA), which also recorded the average
fluorescence (excitation 340 and 380 nm, emission 510 nm)
per well every 3 s to provide Fratio values. Fratio values at every
time point, peak F ratios and area under the curve data were
extracted using SoftMax Pro 5.4.5 (Molecular Devices,
California, USA) software.
Immunocytochemistry
MSCs were seeded onto glass coverslips and incubated at
37 °C for 48 h. All subsequent steps were conducted at room
temperature unless otherwise stated. Culture media was gently
aspirated off the cells and the cells were washed with PBS,
fixed with 4% paraformaldehyde for 15 min and then
permeabilised with 0.25% Triton X-100 for 10 min. Non-
specific binding was blocked with 1% bovine serum albumin
and then the cells were incubated with the appropriate primary
antibody (1:200) overnight at 4 °C. The excess primary anti-
body was removed and successful binding was detected using
rabbit anti-goat (Abcam, Cambridge, UK) or goat anti-rabbit
(Thermo Fisher Scientific, Waltham, MA, USA) Alexa Fluor
488-conjugated secondary antibodies (1:1000 dilution).
Finally, cells were mounted using VectaShield containing
1.5 μg/ml DAPI (Vector Laboratories, Peterborough, UK)
and imaged using a Zeiss AxioPlan 2ie epifluorescent micro-
scope (Carl Zeiss Ltd., Cambridge, UK).
RNA extraction, cDNA synthesis and quantitative
real-time PCR
MSCs were lysed with TRI-reagent and then treated with
100 μl 1-bromo-3-chloropropane and centrifuged to partition
the sample into three phases. The top aqueous phase was then
carefully transferred into a fresh tube and the RNA was pre-
cipitated with isopropanol and washed with 75% ethanol. The
RNAwas then centrifuged at 12,000×g for 10 min, the super-
natant was removed and the RNA pellet was air dried. The
resultant RNAwas then resuspended in molecular grade water
and potential genomic DNA contamination was removed
using a DNA-free™ DNA removal kit (Thermo Fisher
Scientific, Waltham, MA, USA) as per the manufacturer’s
instructions. The purity and quantity of RNA was assessed
using a Nanodrop 2000 (Thermo Scientific, Delaware, USA).
RNA (500 ng for each sample) was primed with 100 ng
random hexamer primers (Bioline, Massachusetts, USA)
by heating the mixture to 70 °C for 10 min. Each sample
was then incubated with 250 μM dNTPs (Bioline, Taunton,
MA, USA), 30 U RNasin ribonuclease inhibitor (Promega,
Madison, WI, USA), 0.01 M DTT, first strand buffer and
200 U Superscript III Reverse transcriptase (RT) (Thermo
Fisher Scientific, Waltham, MA, USA) for 1 h at 42 °C. A
duplicate sample with no RT was run alongside as a con-
trol. The PCR reaction was terminated by heating the sam-
ples to 70 °C for 10 min. Complementary DNA (cDNA)
samples were then stored at − 20 °C.
The cDNA and their corresponding no RT controls were
diluted to 2 ng/μL and mixed with TaqMan™ fast universal
PCR master mix. Commercially available TaqMan gene ex-
pression assay primers and probes for each gene of interest
(GOI) were also added (P2Y1 Hs00704965_s1; P2Y2
Hs04176264_s1 ; P2Y4 Hs00267404_s1 ; P2Y6
Hs00366312_m1; P2Y11 Hs01038858_m1; P2Y12
Hs01881698_s1; P2Y13 Hs03043902_s1; P2Y14
Hs01848195_s1 ; P2X1 Hs00175686_m1; P2X2
Hs04176268_g1; P2X3 Hs01125554_m1; P2X4
Hs00602442_m1; P2X5 Hs01112471_m1; P2X6
Hs01003997_m1; P2X7 Hs00175721_m1; RPLP0
Hs99999902_m1). Each sample was then amplified in a
MicroAmp fast optical 96-well reaction plate on an Applied
Biosystems 7500 Real-Time PCR System (Thermo Fisher
Scientific, Waltham, MA, USA) for 40 cycles. CT values were
extracted from the 7500 software v2.0.6. Receptors with CT
values of below 35 were deemed to be expressed. Ribosomal
protein lateral stalk subunit P0 (RPLP0) was used as an en-
dogenous control to calculate the ΔCT values (ΔCT = average
GOI CT–average RPLP0 CT) and therefore normalise for any
variability in cDNA template input.
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Statistical analysis
Results were analysed, including statistical analyses, using
Origin Pro 2017 software (Origin Lab, Northampton, MA,
USA). All concentration response data were normalised to
the maximal response. In cases of variability between do-
nors, the concentration that produced the maximum re-
sponse in the majority of donors was used. All antagonist
data were normalised to their respective vehicle controls.
Concentration response curves were fitted by Origin using
the Hill Equation. The tau values were calculated by fitting
single exponential decay curves.
Data were assessed for normality using a Shapiro-Wilk
test and then normally distributed data were assessed using
a paired/unpaired Student’s t test or ANOVA with a post
hoc Tukey test. Non-normally distributed data were
assessed by paired sample Wilcoxon signed-rank test,
Mann-Whitney test or Kruskal-Wallis ANOVAwith a post
hoc Dunn’s test. Data are expressed as mean ± SEM of
experiments performed in duplicate using cells from a min-
imum of three independent donors.
Results
Phenotypic characterisation of human
adipose-derived MSCs
The cells used in this study were all plastic adherent
(Fig. 1) and capable of differentiating to mature adipocytes
and osteoblasts when cultured in adipogenic or osteogenic
media respectively (Online resource 1). MSCs were not
capable of spontaneously differentiating to either cell type,
which is consistent with previous findings [21]. MSCs
were strongly positive for expected cell surface markers
CD73 (90.2 ± 2.5% positivity, N = 6 donors), CD90 (89.8
± 2.9% positivity, N = 6 donors) and CD105 (83.7 ± 3.3%
positivity, N = 6 donors), and expressed CD14 (10.0 ±
4.0% positivity, N = 6 donors) and CD45 (11.8 ± 4.3% pos-
itivity, N = 6 donors) at low levels (Fig. 1). These criteria
are in line with the MSC definition outlined by the
International Society for Cellular Therapy [1].
Nucleotides evoked intracellular calcium responses
in AD-MSCs
In the presence of extracellular calcium, ATP, ADP and
UTP elicited concentration-dependent increases in intra-
cellular Ca2+ in all donors tested (N = 7–9 donors)
(Fig. 2). These responses were unaffected by multiple
passaging of the cells (data not shown). Nucleotides had
a rank order of potency ADP (EC50 1.3 ± 1.0 μM) > ATP
(EC50 2.2 ± 1.1 μM) = UTP (3.2 ± 2.8 μM) (Fig. 2a–c).
All three nucleotides elicited an initial rapid response that
decayed to approximately 25% above baseline intracellu-
lar Ca2+ levels within recording period of 250 s (Fig. 2f–
h). Between nucleotides, the magnitude of responses and
net Ca2+ movement were comparable at maximal concen-
trations (Table 1), though responses to ADP decayed
Fig. 1 Phenotypic
characterisation of human
adipose-derived mesenchymal
stromal cells by flow cytometry
and differential interference con-
trast microscopy of mesenchymal
stromal cells in culture. The scale
bar represents 200 μm. Flow cy-
tometric analysis of cell surface
marker expression in human
mesenchymal stromal cells of
known positive (CD73, CD90,
CD105) and negative (CD14 and
CD45) markers. Grey histogram
indicates the isotype control (PE-
conjugated anti-IgG1) and the
black histogram shows the sur-
face antigen expression level.
Data for one representative donor
shown and the percentages
displayed correspond specifically
to this one donor
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significantly faster than responses elicited by ATP or UTP
(p < 0.05, N = 7–9 donors; Table 1).
No responses were detected for 30 μM UDP or below
(N = 6 donors) (Fig. 2i). However, responses were con-
sistently detected in the presence of 300 μM UDP
(N = 6 donors), with some donors displaying very small
responses (peak F ratio 0.12 ± 0.04, N = 3 of 6 donors)
with the addition of 100 μM UDP (Fig. 2d). Agonist
concentrations of above 30 μM UDP are not likely to
be representative of physiological nucleotide concentra-
tions, so it is unlikely that these results show true acti-
vation of UDP-sensitive receptors. Similarly, exogenous
application of UDP-glucose elicited a Ca2+ response in
some donors (N = 3 of 9 donors) (Fig. 2e), but these
responses were only evident at very high agonist concen-
trations of greater than 100 μM (N = 1) or 300 μM (N = 2).
No response was detected for 30 μM UDP-glucose (N = 9
donors) (Fig. 2j). Furthermore, six out of a nine donors
tested did not display a response to UDP-glucose at any
concentration tested (up to 600 μM). The EC50 values for
both UDP and UDP-glucose could not be accurately cal-
culated as the responses had not plateaued within the range
of concentrations tested.
Metabotropic receptors mediated nucleotide-evoked
intracellular calcium responses
The responses elicited by maximal ATP, ADP and UTP con-
centrations persisted, but were decreased by 82.7 ± 3.5% (N =
6, p < 0.001) (Fig. 3a, d), 92.0 ± 4.2% (N = 3, p < 0.05)
(Fig. 4a–b) and 81.8 ± 4.0% (N = 4, p < 0.001) (Fig. 4d–e),
respectively, following removal of Ca2+ from the extracellular
solution with 2 mM EGTA. The nucleotide-evoked responses
also all returned to baseline Ca2+ levels within the sampling
period when extracellular Ca2+ was removed, instead of re-
maining approximately 25% above baseline. In addition, in
the absence of extracellular calcium, ATP-evoked responses
decayed faster (τ 31.2 ± 5.4 s without Ca2+ vs τ 55.0 ± 3.6 s
with Ca2+, p < 0.005; N = 6 donors) and although the re-
sponses to ADP and UTP displayed the same trend, the re-
spective alterations in the decay times were not statistically
significant (Table 2). Also, despite the appearance of a right-
ward shift in the concentration response curves (Fig. 3a, 4a, d),
variation between donors meant that the EC50 values were not
significantly altered for any of the nucleotides when extracel-
lular calcium was removed (Table 2). Furthermore, inhibition
of PLC, which is part of the downstream signalling pathway
Fig. 2 ATP, ADP and UTP elicited intracellular Ca2+ responses in human
adipose-derivedmesenchymal stromal cells (a–e) Concentration response
curves for the magnitude of intracellular Ca2+ responses elicited by (a)
ATP (N = 9 donors), (b) ADP (N = 8 donors), (c) UTP (N = 7 donors), (d)
UDP (N= 6 donors) and (e) UDP-glucose (N= 3 donors). Ca2+ responses
were normalised to the maximal response observed in the majority of
donors, which was the response to 30 μM for ATP, ADP and UTP,
300 μM for UDP and 600 μM for UDP-glucose. Average data for donors
that responded to nucleotide stimulation are shown. Data for donors that
did not respond to nucleotide stimulation were not included. (f–j)
Averaged time-resolved intracellular Ca2+ responses elicited by 30 μM
of each agonist. Traces were normalised to the maximal response within a
donor and averaged across donors. Data points are mean ± SEM
Table 1 Characteristics of the
calcium responses evoked by
maximal concentrations of
nucleotides (30 μM) in primary
human adipose-derived mesen-
chymal stromal cells. Mean ±
SEM
Nucleotide Peak magnitude (F ratio) Net calcium movement
(area under the curve)
Decay time, τ (s) EC50 (μM)
ATP (N = 9) 0.422 ± 0.05 53.7 ± 5.9 73.4 ± 230.2 2.24 ± 1.1
ADP (N = 8) 0.385 ± 0.05 39.6 ± 6.2 35.3 ± 6.3a 1.25 ± 1.0
UTP (N = 7) 0.334 ± 0.06 41.9 ± 7.8 122.4 ± 4447.5 3.24 ± 2.8
a Decay time was significantly faster for the ADP-evoked calcium response vs ATP (p < 0.005) and UTP (p <
0.005) as determined by Kruskal-Wallis ANOVAwith post hoc analysis using Dunn’s test
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instigated upon Gq-coupled P2Y receptor activation, with
U73122 abolished the responses to ATP (N= 6) (Fig. 3b, e),
ADP (N= 4) (Fig. 4c) and UTP (N= 3) (Fig. 4f) respectively.
Also, depleting the endoplasmic reticulum Ca2+ stores by
inhibiting sarco-endoplasmic reticulum Ca2+-ATPases
(SERCA) with thapsigargin (N= 6) (Fig. 3c, f) abolishes the
response to ATP. Together, these data suggest that the nucle-
otide responses in human AD-MSCs are mediated by metab-
otropic receptors and that the magnitude of the response, as
well as the sustained Ca2+ elevation, may be dependent upon
extracellular Ca2+ influx.
Selective antagonists of P2X and P2Y receptors were
employed to determine the molecular basis of the nucleotide-
evoked responses. TheATP response was insensitive to selective
antagonism of P2X4, P2X7, P2Y1, P2Y11, P2Y12 and P2Y13
receptors (N= 6) (Table 3). AR-C118925XX, a selective com-
petitive P2Y2 receptor antagonist [22, 23], caused concentration-
dependent inhibition of the peak response to ATP (IC50
1.1 ± 0.8 μM, N = 7), reaching a plateau inhibition of
73.0 ± 8.5% on average in the presence of 10 μM antagonist
(N = 7) (Fig. 5a–b). Net elevation in intracellular Ca2+ in re-
sponse to ATP, as calculated by the area under the curve, was
inhibited by 81.5 ± 3.3% at maximal concentrations of AR-
C118925XX. Although AR-C118925XX had an inhibitory ef-
fect on the ATP response in all donors tested, there was some
variation between donors. In three of the seven donors tested, the
response to ATP was abolished in the presence of 3 μM antag-
onist. Furthermore, AR-C118925XX abolished UTP-evoked re-
sponses with the same potency as the ATP response (IC50
1.6 ± 0.6 μM, N = 6) (Fig. 5c–d). Together with the observation
that ATP and UTP are equipotent agonists in AD-MSCs, these
data strongly suggest that the ATP and UTP responses are me-
diated by P2Y2 receptor activation.
ADP responses were insensitive to selective antagonism of
P2Y1, P2Y11, P2Y12 and P2Y13 receptors (N = 6) (Table 3).
However, MRS2587, a selective P2Y6 receptor antagonist
[24], displayed potent antagonism (IC50 437 ± 133nM, N =
6) of the ADP response and inhibited the peak response elic-
ited by maximal ADP concentrations by > 80% (Fig. 5e–f).
This antagonist also caused the concentration of intracellular
Ca2+ to drop below baseline calcium post agonist stimulation.
The only other antagonist to affect the response to ADP was
AR-C118925XX, which did not have a significant effect on
the magnitude of the response (≤ 10 μM AR-C118925XX),
Fig. 3 Dependency of ATP-elicited intracellular Ca2+ responses on Ca2+
influx, PLC activity and release of Ca2+ from intracellular stores in human
adipose-derived mesenchymal stromal cells. a ATP dose-response curve
for intracellular Ca2+ responses in the presence (closed circles) and ab-
sence (open circles) of 1.5 mM extracellular Ca2+ (N = 6). b ATP dose-
response curve under control conditions (closed circles) or following
phospholipase C inhibition (10 μM U73122) (N = 6). c ATP dose-
response curve under control conditions (closed circles) or following
sarco-endoplasmic reticulum Ca2+-ATPases inhibition induced emptying
of the intracellular Ca2+ stores (5 μM thapsigargin) (open circles) (N = 6).
dAverage time-resolved trace showing responses elicited by 30 μMATP
in the presence (closed circles) and absence (open circles) of 1.5 mM
extracellular Ca2+ (N = 6). eAverage time-resolved traces for the response
to 30 μM ATP under control conditions (closed circles) and following
U73122 treatment (open circles) (N = 6). f Average time-resolved traces
for the response to 30 μM ATP under control conditions (closed circles)
and following thapsigargin treatment (open circles) (N = 6). Data points
are mean±SEM. *p < 0.05, **p < 0.01, ***p < 0.001
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but caused the response to decay faster which attributed to a
decrease in the net movement of Ca2+ by 37.3 ± 5.8% (p <
0.001, N = 6) (Fig. 5g–h).
mRNA and protein expression of P2 receptors in MSCs
Analysis of mRNA transcripts revealed expression of P2X1,
P2X4, P2X5, P2X6, P2X7, P2Y1, P2Y2, P2Y4 and P2Y6 re-
ceptors in MSCs (N = 6). However, there was heterogeneity in
the expression of P2Y11, P2Y12, P2Y13 and P2Y14 receptors,
as some donors had CT values above 35 for these receptors
(Table 4). In the case of the P2Y12 receptor, only two of the six
donors tested had CT values below 35, but even in these do-
nors the average CT value was 34.4 ± 0.3 (N= 2), indicating
very low expression. P2X2 and P2X3 receptors were not
expressed in any of the donors tested (N = 6) (Table 4).
The protein expression of P2Y1, P2Y2, P2Y4, P2Y6,
P2Y11, P2Y13, P2X1, P2X4, P2X5 and P2X7 receptors was
Fig. 4 Dependency of ADP- and UTP-elicited intracellular Ca2+ re-
sponses on Ca2+ influx and PLC in human adipose-derived mesenchymal
stromal cells. aADP dose-response curve for intracellular Ca2+ responses
in the presence (closed circles) and absence (open circles) of 1.5 mM
extracellular Ca2+ (N = 3). b Average time-resolved trace showing re-
sponses elicited by 100 μM ADP in the presence (closed circles) and
absence (open circles) of 1.5 mM extracellular Ca2+ (N = 3) c Average
time-resolved traces for the response to 30 μM ADP under control con-
ditions (closed circles) and following treatment with 10 μM U73122
(open circles) (N = 4). d UTP dose-response curve for intracellular Ca2+
responses in the presence (closed circles) and absence (open circles) of
1.5 mM extracellular Ca2+ (N = 4). e Average time-resolved trace show-
ing responses elicited by 30 μMUTP in the presence (closed circles) and
absence (open circles) of 1.5 mM extracellular Ca2+ (N = 4) f Average
time-resolved traces for the response to 30 μM UTP under control con-
ditions (closed circles) and following U73122 treatment (open circles)
(N = 3). Data points are mean ± SEM. *p < 0.05, **p < 0.01, ***p <
0.001
Table 2 Changes in the
magnitude, decay kinetics and
potency of nucleotide-evoked
calcium responses in primary hu-
man adipose-derived mesenchy-
mal stromal cells in the presence
and absence of extracellular cal-
cium, [Ca2+]e. Mean ± SEM
Nucleotide Peak magnitude (F ratio)a Decay time, τ (s) EC50 (μM)
+ [Ca2+]e − [Ca2+]e + [Ca2+]e − [Ca2+]e + [Ca2+]e − [Ca2+]e
30 μM ATP (N = 6) 0.68 ± 0.1 0.11 ± 0.03 55.0 ± 3.6 31.2 ± 5.4b 0.9 ± 0.4 5.7 ± 2.6
100 μM ADP (N = 3) 1.08 ± 0.1 0.17 ± 0.1 30.3 ± 1.4 22.5 ± 72.4 0.8 ± 0.6 28.3 ± 62.1
30 μM UTP (N = 4) 0.57 ± 0.04 0.12 ± 0.02 59.7 ± 27 41.2 ± 5.9 8.3 ± 1.4 7.8 ± 2.8
a The peak magnitude was significantly decreased when extracellular calcium is removed for ATP (p < 0.001),
ADP (p < 0.05) and UTP (p < 0.001) as determined by paired T tests or Wilcoxon signed-rank test
b The decay time was significantly faster for the ATP-evoked calcium response in the absence of extracellular
calcium (p < 0.005) as determined by a paired T test
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confirmed by immunocytochemistry. These P2 receptors ap-
pear to be distributed quite uniformly throughout the
cytoplasm/cell membrane, with P2Y1 and P2X7 receptors also
displaying staining in the nuclear/perinuclear regions. Very
faint positive staining was observed for P2Y13 and P2X5
receptors. No staining was observed for the P2Y12 receptor
(Fig. 6 and Online resource 2).
In summary, these results suggest that although a wide rep-
ertoire of P2 receptors were detected by qRT PCR and immu-
nocytochemistry, only P2Y2 and P2Y6 receptors play a func-
tional role in the nucleotide-evoked Ca2+ responses in MSCs.
Table 3 The effect of P2 subtype-selective antagonism on the nucleotide-evoked calcium responses in primary human adipose-derived mesenchymal
stromal cells. The number of independent donor cells used (N number) is indicated within round brackets in the maximum inhibition and IC50 columns
Selective
antagonist
Receptor
target
Nucleotide
[concentration,
μM]
Antagonist
range, μM
Maximum inhibition
(%)a [antagonist
concentration, μM]
IC50, μM
a Reference
PSB-12062 P2X4 ATP [100] 0.003–30 ns – [57]
A438079 P2X7 ATP [1000] 0.003–10 ns – [58]
MRS2500 P2Y1 ATP [30] 0.0001–1 ns – [59]
ADP [30] 0.0001–1 ns –
AR-C118925XX P2Y2 ATP [30] 0.003–30 73.0 ± 8.5 [10] (7) 81.5 ± 3.3 [10] (5) 1.1 ± 0.8 (7) 2.9 ± 1.1 (5) [22, 23]
ADP [30] 0.003–30 18.2 ± 6.6 [30] (6) 53.9 ± 5.1 [30] (6) 0.64 ± 0.4 (6) 9.6 ± 1.6 (6)
UTP [30] 0.003–30 100 [30] (6) 100 [30] (6) 1.6 ± 0.6 (6) 0.84 ± 0.5 (6)
MRS2578 P2Y6 ADP [30] 0.003–10 79.4 ± 9.6 [10] (6) 166.9 ± 27.3 [10] (6) 0.44 ± 0.1 (6) 0.29 ± 0.1 (6) [24]
NF340 P2Y11 ATP [30] 0.003–10 ns – [60]
ADP [30] 0.003–10 ns –
PSB-0739 P2Y12 ATP [30] 0.003–10 ns – [61]
ADP [30] 0.003–10 ns –
MRS2211 P2Y13 ATP [30] 0.003–10 ns – [62]
ADP [30] 0.003–3 ns –
a IC50 values and max % inhibition values were calculated with the peak magnitude values (top) and area under the curve data (bottom) for each agonist/
antagonist combination. ns indicates no significant inhibition at any concentration of antagonist tested
Fig. 5 Effect of P2Y2 and P2Y6 receptor antagonism on ATP, ADP and
UTP-elicited intracellular Ca2+ responses in human adipose-derived mes-
enchymal stromal cells. a Dose inhibition curve showing the effect of a
selective P2Y2 receptor antagonist (AR-C118925XX) on intracellular
Ca2+ responses elicited by 30 μM ATP (N = 7 donors). b Average time-
resolved trace showing ATP-elicited Ca2+ response (30 μM) in the ab-
sence (closed circles) and presence (open circles) of AR-C118925XX
(10 μM) (N = 7 donors). c Dose inhibition curve showing the effect of
AR-C118925XX on intracellular Ca2+ responses elicited by 30 μMUTP
(N = 7 donors). dAverage time-resolved trace showingUTP-elicited Ca2+
response (30 μM) in the absence (closed circles) and presence (open
circles) of AR-C118925XX (10 μM) (N = 7 donors). e Dose inhibition
curve showing the effect of selective antagonism of P2Y6 receptors with
MRS2578 on intracellular Ca2+ responses elicited by 30 μMADP (N = 7
donors). f Average time-resolved trace showing ADP-elicited Ca2+ re-
sponse (30 μM) in the absence (closed circles) and presence (open
circles) of MRS2578 (10 μM). g Effect of AR-C118925XX on net
Ca2+ movement evoked by ADP (30 μM) (N = 6 donors). h Average
time-resolved trace showing ADP-elicited Ca2+ response (30 μM) in
the absence (closed circles) and presence (open circles) of AR-
C118925XX (10 μM). Data points are mean ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001
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Discussion
This study provides clear evidence of functional P2 receptors
in primary human AD-MSCs. Robust changes in intracellular
calcium levels were observed with exogenous nucleotide
stimulation of these cells. The abolishment of the ATP-
elicited response by both emptying the ER calcium stores
and inhibiting PLC, as well as the persistence of the response
in the absence of extracellular calcium, suggests that the re-
sponse is mediated by metabotropic P2Y receptors via the
Gα,q/11-PLC-IP3R pathway. The potency of the response re-
mains unchanged in the presence and absence of extracellular
calcium, suggesting that the same receptors are likely to be
activated in both cases. However, the magnitude of the re-
sponse to ATP is diminished by the removal of extracellu-
lar calcium. This may be due to partial emptying of the
intracellular calcium stores as the cell attempts to maintain
calcium homeostasis without calcium influx, leading to
less calcium being available to respond to receptor activa-
tion. Alternatively, the magnitude of the response may be
dependent on extracellular Ca2+ entry as well as Ca2+ re-
lease from intracellular stores. Removal of extracellular
Ca2+ eliminates the lingering increase in intracellular
Ca2+ evoked by nucleotide application, which may indicate
that this latter plateau phase is due to store-operated Ca2+
entry (SOCE). Purinergic signalling via P2Y receptors has
previously been shown to lead to SOCE [25, 26].
The presence of a UTP-evoked calcium response in hu-
man AD-MSCs may be indicative of P2Y4 receptor in-
volvement. Unfortunately, there is currently no commer-
cially available selective antagonist for P2Y4 receptors
[27], so it is not possible to conclusively eliminate the pos-
sibility that P2Y4 receptors may have a role in the UTP-
evoked calcium response; however, the evidence presented
here strongly supports the hypothesis that the ATP and UTP
responses are mediated by P2Y2 receptors. The calculated
EC50 values for ATP and UTP and the IC50 values in the
presence of a selective P2Y2 receptor antagonist are com-
parable, which fits with reports that ATP and UTP act
equipotently on P2Y2 receptors [28], whereas P2Y4
Fig. 6 Analysis of P2Yand P2X receptor immunofluorescence in human
adipose-derived mesenchymal stromal cells (MSCs). Images taken with a
× 63 objective on a Zeiss AxioPlan 2ie epifluorescent microscope of
permeabilised MSCs labelled with primary antibodies against receptor
targets and visualised with an Alexa Fluor 488-conjugated secondary
antibody (green). Cells are counterstained with DAPI to visualise nuclei
(blue). The exposure and camera settings were consistent across all the
images taken for each donor. Images presented are representative of at
least ten fields of view of cells from three independent donors. Scale bar
represents 30 μm
Table 4 The mRNA expression profile of P2X and P2Y receptors in
primary human adipose-derived mesenchymal stromal cells. Genes with
CT values of ≤ 35 were considered present and the average CT values
shown were calculated from CT values below this threshold only. Cases
of donor variation are indicated by a b c. Data was collected for six inde-
pendent donors and shown as mean ± SEM
Receptor CT value Normalised to RPLP0
expression (ΔCT)
P2X1 30.4 ± 0.4 11.3 ± 0.6
P2X2 Not detected –
P2X3 37.8 ± 0.3 –
P2X4 25.8 ± 0.3 6.3 ± 0.6
P2X5 30.6 ± 1.3 12.8 ± 0.4
P2X6 32.9 ± 0.5 13.7 ± 0.7
P2X7 31.6 ± 0.2 12.1 ± 0.7
P2Y1 29.0 ± 0.8 11.2 ± 0.7
P2Y2 31.6 ± 0.5 13.8 ± 0.2
P2Y4 30.9 ± 0.5 13.1 ± 0.2
P2Y6 29.4 ± 0.8 10.4 ± 0.6
P2Y11 31.4 ± 0.7
a 13.3 ± 0.8a
P2Y12 34.4 ± 0.3
b 17.3 ± 0.6b
P2Y13 33.0 ± 0.6
c 15.2 ± 0.5c
P2Y14 32.8 ± 0.5
c 14.9 ± 0.4c
aMean ± SEM for 4/6 donors
bMean ± SEM for 2/6 donors
cMean ± SEM for 5/6 donors
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receptors are antagonised by ATP [29, 30]. In addition, the
ATP responses are blocked and the UTP responses are
abolished by a P2Y2 receptor-selective antagonist, which
strongly suggests P2Y2 receptor involvement, and pre-
cludes P2Y4 receptor contribution. It has recently been
suggested that the P2Y2 receptor may play a role in driv-
ing BM-MSC adipogenesis while suppressing osteogene-
sis, without effecting the rate of cell proliferation [31]. It
may be that P2Y2 receptors are involved in a similar role
in AD-MSCs. If this was the case, this could provide an
opportunity to develop pharmacological tools to target the
P2Y2 receptor specifically to drive MSCs towards/away
from an adipogenic phenotype in vivo, thus providing a
route to control the number of new adipocytes present in
adipose tissue and potentially regulate weight gain.
It is important to note that although selective P2Y2 re-
ceptor antagonism abolishes the response to UTP, approx-
imately 25% of the peak ATP response is resistant to the
effects of AR-C118925XX. This residual response may be
simply due to the competitive nature of the antagonist or
due to the liberation of ADP (and/or AMP and adenosine)
from ATP by ectonucleotidases, such as CD39 [32, 33],
resulting in the activation of other P2 receptors. This may
also explain the variation in the level of inhibition ob-
served between donors, which may be due to the differing
efficiencies of ectonucleotidase activity per donor. No ge-
netic analysis of the donors used in this study was conduct-
ed, but previous reports suggest that mutations in the
ENTPD1 (CD39) gene can lead to a reduction in the activ-
ity of CD39 [34] and there have also been reports to sug-
gest that CD39 surface expression levels are dynamic and
can increase under certain conditions [35].
A robust ADP response was resistant to inhibition in the
presence of all the antagonists tested, excluding AR-
C118925XX (P2Y2) and MRS2578 (P2Y6) . AR-
C118925XX only significantly inhibited the net movement
of Ca2+ in the latter decay phase of the response to ADP and
not the initial peak. ADP is not the preferred agonist for P2Y2
receptors, so these results may indicate indirect activation of
the P2Y2 receptor via ADP-induced release of ATP [26]. The
ADP response was also inhibited by MRS2578. ADP has
been shown to elicit a calcium response in 1321N1 astrocyto-
ma cells over-expressing P2Y6 receptors, but its effects are
much less potent than the preferred agonist of P2Y6 receptors,
UDP [36], so it was surprising that MRS2578 abolished the
response to ADP in MSCs, when these cells lack a UDP-
elicited Ca2+ response. It is important to note that UDP does
elicit a Ca2+ response in MSCs, but only at very high agonist
concentrations that are more than ten-fold higher than concen-
trations required to maximally active the P2Y6 receptor [36].
One possible explanation for this may be that P2Y6 receptors
exist as a heterodimer, which has led to an altered agonist
profile in these cells. P2Y6 receptors have been shown to form
heterodimers with other GPCRs [37, 38] and hetero-
oligomerization of other P2Y receptors can alter the agonist
sensitivity of these receptors [39]. After the initial peak, block-
ade of the ADP response withMRS2578 leads to a decrease in
the concentration of intracellular Ca2+ to below baseline Ca2+
levels, suggesting there is either efflux or internalisation of
Ca2+. It is unclear why P2Y6 receptor inhibition would have
this effect and these observations imply that the role of the
P2Y6 receptor inMSCs is complex. P2Y6 receptors have been
shown to promote osteogenesis in BM-MSCs [40] and has
also been implicated in increasing IL-6 expression [41]. It
has been suggested that IL-6 is important for maintaining the
immunoprivilege stasis ofMSCs [42], so if P2Y6 receptors are
involved in IL-6 secretion it may prove to be a valuable target
for prolonging MSC viability for therapeutic use. However,
much more additional work is required to clarify both the
molecular mechanism and functional role of P2Y6 receptor
activation in these cells.
Despite evidence to suggest the presence of P2X recep-
tors in AD-MSCs, no functional evidence for ionotropic
involvement in the nucleotide-evoked Ca2+ responses was
observed. A previous study conducted by Zippel et al.
(2012) also detected P2X receptors in AD-MSCs, but in-
terestingly although they did not detect P2X1 receptor
expression at the mRNA level, they demonstrated that
use of P2X1 receptor-selective antagonist, NF279, was
able to inhibit the ATP-evoked calcium response [43].
This discrepancy may be explained by the fact they used
extremely high concentrations of NF279 (100 μM) which
is likely to non-specifically block other P2 receptors as
well [44]. P2X4 receptors are known to localise to lyso-
somes and traffic to and from the plasma membrane in
other cell types [45, 46], so one explanation for the lack
of effect of P2X4 receptor antagonism is that very few
P2X4 receptors are expressed at the cell surface. Other
groups have demonstrated presence of P2X7 receptors in
mesenchymal stem cells [47], but in this study, we were
unable to demonstrate functional P2X7 receptors, possibly
due the use of insufficiently elevated concentrations of
ATP in this study or the unusual localisation of the
P2X7 receptor in the nuclear/perinuclear region. P2Y1
and P2Y11 receptors were also detected at the mRNA
and protein level, but selective antagonism of these recep-
tors did not suggest a role for either receptor in the
nucleotide-evoked Ca2+ responses in these cells. A possi-
ble explanation for this is that P2Y2 receptor activation
caused heterologous desensitisation of these subtypes
[48]. As well as being found throughout the cell, like
the P2X7 receptor, the P2Y1 receptor also appears to be
located in the nuclear/perinuclear region, and this may be
a reason for the lack of P2Y1 receptor involvement in the
response to exogenous nucleotide application. It is unclear
why these receptors are detected close to the nucleus in
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these cells. Antagonism of the Gi-coupled P2Y12 and
P2Y13 receptors had no effect on the Ca
2+ response.
P2Y12 receptors do not appear to be expressed at the pro-
tein level in these cells.
It must be acknowledged that there are several P2 re-
ceptors that were detected at the mRNA level, but were
excluded from further study. Current evidence suggests
both P2X5 and P2X6 receptors are non-functional in
humans [49–51]. The response to the P2X1 receptor rap-
idly desensitises, so it is unlikely to be detected with a
FlexStation III. Finally, there was no functional Ca2+ re-
sponse detected at physiologically relevant concentrations
of UDP-glucose, the preferred agonist of P2Y14 receptors.
Responses to UDP-glucose were only detected at very
high concentrations of agonist, but previous reports sug-
gest that 10 μM UDP-glucose is sufficient to maximally
activate P2Y14 receptors [52].
It must also be noted that there are several limitations
associated with this study. Firstly, only female patients
were recruited and no information about ethnicity or life-
style was collected. The mean age of the recruited donors
is 55.5 ± 1.4, and ageing has been shown to increase cel-
lular senescence and AD-MSCs extracted from elderly
patients (age 60–73) have been shown to have diminished
migration and differentiation capabilities [53]. The molec-
ular mechanisms underlying these changes are not fully
understood, so it is not possible to rule out potential
changes in the P2 receptor expression and/or functioning
as a possible cause. However, data presented by Zippel et
al. (2012) included younger donors and they demonstrated
functional response to both ATP and UTP in AD-MSCs
extracted from younger patients and they also detected a
very similar P2 receptor profile to the profile determined
in this study [43]. However, it is important to note that
Zippel et al. (2012) only used cells isolated from a total of
three donors, so a much more extensive study would be
required to clarify whether the results presented here are
applicable to younger donors as well. This means the data
presented here is limited to profiling the P2 receptor re-
sponses in AD-MSCs extracted from older women. Also,
although all the recruited patients were cancer-free at the
time of recruitment, each donor has been treated for breast
cancer in the past. Although previous reports suggest
some chemotherapeutic agents do not affect surface mark-
er expression, proliferation and differentiation of AD-
MSCs [54], it is not known whether cancer and/or subse-
quent cancer treatment causes long-term alterations in the
expression and function of purinergic receptors in these
cells. Perhaps the most important limitation of the study is
the use of an in vitro system. Cell culture has been previ-
ously shown to cause changes in the behaviour of MSCs
[8, 55, 56], so this in vitro model may not accurately
reflect conditions in vivo. This study depends heavily on
the selectivity of available pharmacological probes and
antibodies. Although all the pharmacological antagonists
used in this study are reported to be selective for their
target receptor, it is not possible to rule out the possibility
that these antagonists affect non-specific targets in these
cells. Finally, all the pharmacological data presented here
is based on analysis of population level response, which
does not account for cell-to-cell variation in response pat-
terns. Single-cell calcium imaging would be a good meth-
od to investigate any heterogeneity within the population.
In summary, we have demonstrated that all the known
P2 receptors are expressed in human AD-MSCs, exclud-
ing P2X2, P2X3 and P2Y12 receptors, but some heteroge-
neity in the expression of P2Y11, P2Y13 and P2Y14 recep-
tors exists. Despite confirmation of the presence of recep-
tors at both the mRNA and protein level, only two P2
receptors, P2Y2 and P2Y6, appear to be involved in gen-
erating functional nucleotide-evoked Ca2+ responses. It is
likely that the other P2 receptors play a functional role in
these cells, but this study suggests that they are not pri-
marily involved in changing intracellular Ca2+ levels in
response to exogenous nucleotide stimulation. They may
be involved in non-Ca2+-dependent pathways, only acti-
vated under certain circumstances or have intracellular
functions which are beyond the scope of this study.
There has already been a lot of research into the role of
P2 receptors in BM-MSCs, which suggests that P2Y2 and
P2Y6 receptors are important in driving adipogenic and
osteogenic differentiation respectively [20, 31, 40]; it is
possible that these receptors may play a similar role in
AD-MSCs as well. If so, targeting these receptors to drive
adipogenesis may provide a novel method of controlling
adipose tissue expansion and weight gain and/or help in
efforts to improve the therapeutic potential of MSCs.
Much more research is needed to elucidate the role of
these receptors in vivo, but this study provides a solid
foundation from which to begin.
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